CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy
Most Cited Paper
in CRISPR and Genetic Engineering
18 Months Post-Publication
Class of 2026
“CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/crispr-and-genetic-engineering/2026/
Topics
CRISPR-Cas9 gene editing · Nexiguran ziclumeran · ATTR cardiomyopathy · serum TTR level · NT-proBNP · high-sensitivity cardiac troponin T · 6-minute walk distance · NYHA class · variant ATTR-CM · infusion-related reactions · transient liver-enzyme elevations · single intravenous infusion · phase 1 open-label trial · TTR reduction · Nexiguran ziclumeran
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited CRISPR and Genetic Engineering Papers, Class of 2026. https://pri.pepkio.com/top-papers/crispr-and-genetic-engineering/2026. Accessed 2026-07-21. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459